

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Hutchison Whampoa Limited

(incorporated in Hong Kong with limited liability)

(Stock Code: 13)

OVERSEAS REGULATORY ANNOUNCEMENT

Please refer to the attached announcement of Hutchison China MediTech Limited, which is listed on the Alternative Investment Market operated by the London Stock Exchange and a 71.6% owned subsidiary of Hutchison Whampoa Limited.

As at the date of this announcement, the Directors of the Company are:

Executive Directors:

Mr LI Ka-shing (*Chairman*)
Mr LI Tzar Kuoi, Victor (*Deputy Chairman*)
Mr FOK Kin-ning, Canning
Mrs CHOW WOO Mo Fong, Susan
Mr Frank John SIXT
Mr LAI Kai Ming, Dominic
Mr KAM Hing Lam

Non-executive Directors:

Mr George Colin MAGNUS
Mr William SHURNIAK

Independent Non-executive Directors:

The Hon Sir Michael David KADOORIE
Mr Holger KLUGE
Mrs Margaret LEUNG KO May Yee
Mr William Elkin MOCATTA
*(Alternate to The Hon Sir Michael
David Kadoorie)*
Mr WONG Chung Hin

Hong Kong, 30 June 2009



HUTCHISON CHINA MEDITECH LTD

**Hutchison China MediTech Limited (“Chi-Med”)
(AIM: HCM)**

Blocklisting Six Monthly Return

London: Tuesday, 30 June 2009: Chi-Med announces the following blocklisting six monthly return:

1. Name of applicant:	Hutchison China MediTech Limited
2. Name of scheme:	Hutchison China MediTech Limited Share Option Scheme
3. Period of return:	From 29 December 2008 to 28 June 2009
4. Balance under scheme from previous return:	2,543,553 ordinary shares of US\$1 each
5. The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return:	Nil
6. Number of securities issued/allotted under scheme during period:	Nil
7. Balance under scheme not yet issued/allotted at end of the period:	2,543,553 ordinary shares of US\$1 each
8. Number and class of securities originally listed and the date of admission:	2,560,606 ordinary shares of US\$1 each admitted on 26 June 2007
9. Total number of securities in issue at the end of the period:	51,229,174 ordinary shares of US\$1 each.
Name of contact:	Christian Hogg
Address of contact:	21/F., Hutchison House, 10 Harcourt Road, Hong Kong
Telephone number of contact:	+852 2121 8200

Ends

Enquiries

Chi-Med

Christian Hogg, CEO

Telephone: +852 2121 8200

Citigate Dewe Rogerson

Anthony Carlisle

David Dible

Telephone: +44 (0) 20 7638 9571

+44 (0) 7973 611 888

+44 (0) 7967 566 919

About Chi-Med

Chi-Med is the holding company of a pharmaceutical and healthcare group based primarily in China and was admitted to trading on the Alternative Investment Market of the London Stock Exchange in May 2006. It is focused on researching, developing, manufacturing, and selling pharmaceuticals, health supplements and other consumer health and personal care products derived from Traditional Chinese Medicine and botanical ingredients.

Chi-Med is majority owned by Hutchison Whampoa Limited, an international company listed on the Main Board of The Stock Exchange of Hong Kong Limited.